ArticleCell & bioscience2026
The transmembrane segments of SARS-CoV-2 nsp3 govern viral intracellular trafficking.
Article in Cell & bioscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
After entry, coronaviruses deliver their genomic RNA to the ER-Golgi intermediate compartment to build replication organelles, yet how the RNA first contacts membranes is unclear. Here, we demonstrate that the first transmembrane helix of nsp3 serves as an address code, inserting into the ER via SEC61A1 during translation and is then escorted to the ERGIC by the COPII factors SAR1A and LMAN1. Deletion or proline substitution of key residues in this helix trapped the RNA in the cytosol and crippled viral replication. A 24-residue peptide (Y24) modeled on the helix inhibited viral replication, and AAV9-delivered A20-2 peptide reduced lung viral RNA and pathology in mice. This host-targeted approach offers a potential broad-spectrum strategy against emerging coronaviruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.